IRIS
RUPERTO, NICOLINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.866
AS - Asia 819
NA - Nord America 332
SA - Sud America 69
AF - Africa 21
OC - Oceania 3
Totale 7.110
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.718
SG - Singapore 353
US - Stati Uniti d'America 318
CN - Cina 195
VN - Vietnam 149
FR - Francia 58
BR - Brasile 46
HK - Hong Kong 36
FI - Finlandia 31
BD - Bangladesh 15
DE - Germania 13
JP - Giappone 11
AR - Argentina 10
GB - Regno Unito 10
ID - Indonesia 8
IN - India 8
IQ - Iraq 7
RU - Federazione Russa 6
CA - Canada 5
DZ - Algeria 5
KE - Kenya 5
SE - Svezia 5
TR - Turchia 5
TW - Taiwan 5
CH - Svizzera 4
EC - Ecuador 4
MX - Messico 4
NL - Olanda 4
PK - Pakistan 4
CO - Colombia 3
EG - Egitto 3
IL - Israele 3
TH - Thailandia 3
AL - Albania 2
AT - Austria 2
BY - Bielorussia 2
CL - Cile 2
CR - Costa Rica 2
JO - Giordania 2
LB - Libano 2
MA - Marocco 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PL - Polonia 2
TN - Tunisia 2
VE - Venezuela 2
ZA - Sudafrica 2
AM - Armenia 1
AU - Australia 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GM - Gambi 1
GR - Grecia 1
IE - Irlanda 1
JM - Giamaica 1
KR - Corea 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MD - Moldavia 1
MY - Malesia 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
TG - Togo 1
TJ - Tagikistan 1
UA - Ucraina 1
UY - Uruguay 1
Totale 7.110
Salva come PNG Salva come JPEG
Città #
Genova 2.907
Genoa 1.770
Rapallo 521
Vado Ligure 468
Singapore 176
San Jose 106
Ashburn 83
Lauterbourg 46
Ho Chi Minh City 41
Hanoi 37
Hong Kong 36
Beijing 32
Helsinki 31
New York 17
Council Bluffs 15
Haiphong 13
Bordighera 12
Santa Clara 12
Frankfurt am Main 10
Tokyo 10
Orem 9
Los Angeles 6
Da Nang 5
Amsterdam 4
Chicago 4
Nairobi 4
Paris 4
São Paulo 4
Zurich 4
Alessandria 3
Baghdad 3
Bangkok 3
Buffalo 3
Can Tho 3
City of London 3
Istanbul 3
Phủ Lý 3
Quito 3
Rio de Janeiro 3
Shanghai 3
Sona 3
Tianjin 3
Amman 2
Biên Hòa 2
Blumenau 2
Bogotá 2
Buenos Aires 2
Bắc Ninh 2
Carapicuíba 2
Cardiff 2
Chennai 2
Dallas 2
Delhi 2
Des Moines 2
Gothenburg 2
Guangzhou 2
Hải Dương 2
Jakarta 2
London 2
Milan 2
Montreal 2
Naples 2
New Delhi 2
New Taipei City 2
Nuremberg 2
Poplar 2
Pune 2
Quảng Ngãi 2
Rawalpindi 2
Rostov-on-Don 2
Stockholm 2
São Gonçalo 2
Taipei 2
Tirana 2
Valenza 2
Villaricca 2
Vĩnh Long 2
Warsaw 2
Abū Ḩammād 1
Acalanes Ridge 1
Al Mansurah 1
Alajuela 1
Alfenas 1
Almaty 1
Altoona 1
Andradina 1
Ankara 1
Avellaneda 1
Bacoor 1
Bari 1
Barranquilla 1
Barueri 1
Batna City 1
Bauru 1
Belgrade 1
Belo Horizonte 1
Benoni 1
Birigui 1
Blida 1
Brockton 1
Totale 6.520
Salva come PNG Salva come JPEG
Nome #
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 212
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 199
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 195
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 192
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 187
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 185
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 179
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 174
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation collaborative initiative 173
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 172
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 170
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 167
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 164
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 162
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 159
A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry 157
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 151
Clinical trials in children and adolescents with systemic lupus erythematosus: Methodological aspects, regulatory landscape and future opportunities 147
Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. 141
Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open‐label, Randomized Phase IIIb/IV Study 140
The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry 135
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 134
An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA) 133
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus 131
Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study 128
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 127
Current and future perspectives in the management of juvenile idiopathic arthritis 122
Current medical treatments for juvenile idiopathic arthritis 120
The PRINTO juvenile dermatomyositis trial - Authors' reply 113
The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry 112
Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative 111
Treatment of juvenile idiopathic arthritis: what's new? 111
Development and testing of reduced versions of the MMT-8 in juvenile dermatomyositis 108
Health-related quality of life of patients with juvenile idiopathic arthritis coming from 3 different geographic areas. The PRINTO multinational quality of life cohort study 108
Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: Results from the 5-year long-term extension of the phase III pivotal trials 106
A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis 106
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: Results of a multicentre, double-blind, randomised-withdrawal trial 105
Treating juvenile idiopathic arthritis to target: Recommendations of an international task force 104
Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus 99
Measuring Disease Damage and Its Severity in Childhood-Onset Systemic Lupus Erythematosus 96
Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis 94
Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: Post hoc radiographic analysis from two randomized controlled trials 93
Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial 92
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: Results of a phase 1, open-label, multicenter study 90
Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitisrelated arthritis, or psoriatic arthritis 89
Development and initial validation of parent and child versions of the Juvenile Arthritis Disease Activity Score 87
International consensus for a definition of disease flare in lupus 87
Extrapolation or controlled trials in paediatrics: The current dilemma 75
Disease activity, overweight, physical activity and screen time in a cohort of patients with juvenile idiopathic arthritis 74
Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis? 72
Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial 69
Validation of the PEDiatric Behçet’s Disease classification criteria: an evidence-based approach 64
Defining criteria for disease activity states in juvenile dermatomyositis based on the Juvenile Dermatomyositis Activity Index 59
Validity and Reliability of Four Parent/Patient-Reported Outcome Measures for Juvenile Idiopathic Arthritis Remote Monitoring 54
Preface 54
Outcome Scores in Pediatric Rheumatology 51
Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers 50
Daily Living Activity Dataset of Juvenile Rheumatic Patients From Wearables Data 45
Paediatric rheumatologists do not score the physician's global assessment of juvenile idiopathic arthritis disease activity in the same way 35
Towards the definition of disease phenotypes in paediatric SAPHO syndrome: a national multicentric study 29
Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study 22
Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world 15
Physician's global assessment of disease activity in juvenile idiopathic arthritis: consensus-based recommendations from an international task force 14
Clinical features, treatment and outcomes of Italian children with enthesitis-related arthritis and juvenile psoriatic arthritis: a cross-sectional cohort study 14
Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial 10
Factors for Consideration by Pediatric Rheumatologists When Scoring the Physician Global Assessment of Disease Activity in Juvenile Idiopathic Arthritis: First Step Toward an Internal Consensus 4
Totale 7.309
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.499
article - articoli 25.499
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.998
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021191 0 0 0 0 0 0 0 0 0 109 19 63
2021/2022650 65 30 30 54 14 62 17 133 61 68 28 88
2022/2023631 59 76 8 44 114 78 16 41 99 8 80 8
2023/2024428 33 47 13 54 43 65 19 30 18 17 22 67
2024/20251.209 38 75 57 64 127 152 104 235 36 72 119 130
2025/20261.958 270 64 96 108 321 183 357 111 215 233 0 0
Totale 7.309